. Author manuscript; available in PMC: 2022 Sep 1.

Published in final edited form as: Am J Transplant. 2021 Mar 17;21(9):3066–3076. doi: 10.1111/ajt.16538

Table 3.

Immunologic outcomes: biopsies and rejection

Subject	Time (m)	Pathology	DSA	Action/Comment	Study Completion
q1m
009	6	Borderline	N	Oral steroid pulse	Y
009	10	Borderline	N	Oral steroid pulse	Y
q2m
078	6	1A ACR	N	IV steroid pulse, converted to q1m	N
078	6	1A ACR	N	NC with MMF, prednisone, belatacept	N
098	8	1B ACR	Y	Thymoglobulin, converted to q1m	N
098	8	1B ACR	Y	NC with MMF, prednisone	N
130	4	1A ACR	N	Converted to q1m	Y
135	4	1B ACR, AMR	Y	Thymoglobulin, plasmapheresis/IVIG	N
				Converted to q1m
				NC with MMF
151	6	Normal	Y	Converted to q1m	Y

m, months; ACR, acute cellular rejection; Oral steroid pulse, 100 mg prednisone PO for 5 days; IV steroid pulse, 10 mg/kg methylprednisolone IV daily for 3 days followed by an oral prednisone taper over 6 weeks; NC, non-compliant; MMF, mycophenolate mofetil; AMR, antibody mediated rejection